Acta Pharmaceutica Sinica B
|
2026, 16(8): 5016-5033
• Perspective •
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders
Full
Affiliations
doi: 10.1016/j.apsb.2026.06.035
Outline
The melanocortin-4 receptor (MC4R) is a key regulator of energy balance and a potential target for weight management. Early drug discovery endeavors were hindered by incomplete understanding of its signal transduction mechanisms and broad activation of Gs pathways. Recent advances indicate that MC4R elicits multiple intracellular responses, with Gq/₁₁ signaling in the paraventricular nucleus (PVN) neurons playing a central role in appetite suppression. High-resolution cryo-electron microscopy structures of MC4R, such as the setmelanotide-MC4R-Gq complex reported here, provide valuable insights into ligand binding, receptor activation, and biased signaling, thereby enabling the design of more selective agonists with improved safety profiles. Combination therapies targeting MC4R alongside glucagon-like peptide-1 mimetics and other agents regulating metabolic pathways have shown promise to enhance weight loss. MC4R modulators are also implicated in treating other disorders, including melanocortin signaling dysfunction. These progresses call for renewed efforts in developing the next-generation MC4R-based therapies against metabolic diseases.
MC4R
/
Biased
/
Signaling
/
Structure
/
Obesity
.
药学学报(英文版),
2026
, 16
(8)
: 5016
-5033
.
DOI: 10.1016/j.apsb.2026.06.035
Wenbo Feng, Qingtong Zhou, Ming-Wei Wang.
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(8)
: 5016
-5033
.
DOI: 10.1016/j.apsb.2026.06.035
Year 2026 volume 16 Issue 8
PDF
77
17
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.06.035
- Receive Date:2025-12-05
- Online Date:2026-09-17